<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="in MELD score. Conclusion Treatment of HCV-related LC patients with" exact="sofosbuvir" post="and daclatasvir with or without ribavirin for 3 or"/>
 <result pre="score. Conclusion Treatment of HCV-related LC patients with sofosbuvir and" exact="daclatasvir" post="with or without ribavirin for 3 or 6 months"/>
 <result pre="HCV-related LC patients with sofosbuvir and daclatasvir with or without" exact="ribavirin" post="for 3 or 6 months showed high SVR and"/>
 <result pre="Exposure and Outcome Medications The treated patients have been given" exact="sofosbuvir" post="400 mg plus daclatasvir 60 mg plus ribavirin daily"/>
 <result pre="The treated patients have been given sofosbuvir 400 mg plus" exact="daclatasvir" post="60 mg plus ribavirin daily for 3 months or"/>
 <result pre="been given sofosbuvir 400 mg plus daclatasvir 60 mg plus" exact="ribavirin" post="daily for 3 months or sofosbuvir 400 mg plus"/>
 <result pre="daclatasvir 60 mg plus ribavirin daily for 3 months or" exact="sofosbuvir" post="400 mg plus daclatasvir 60 mg daily for 6"/>
 <result pre="ribavirin daily for 3 months or sofosbuvir 400 mg plus" exact="daclatasvir" post="60 mg daily for 6 months in patients who"/>
 <result pre="apart from headache and fatigue in patients who responded to" exact="paracetamol" post="treatment. Rather, few patients who have received Ribavirin have"/>
 <result pre="the ALLY-1 trial looks at the effects of Daclatasvir/Sofosbuvir with" exact="ribavirin" post="on patients with advanced cirrhosis, including decompensated cirrhosis across"/>
 <result pre="colleague have said.27 Conclusion Treatment of HCV-related LC patients with" exact="sofosbuvir" post="and daclatasvir with or without ribavirin for 3 or"/>
 <result pre="said.27 Conclusion Treatment of HCV-related LC patients with sofosbuvir and" exact="daclatasvir" post="with or without ribavirin for 3 or 6 months"/>
 <result pre="HCV-related LC patients with sofosbuvir and daclatasvir with or without" exact="ribavirin" post="for 3 or 6 months shows high SVR and"/>
 <result pre="Gastroenterology. 2018;155(2):411â€“421. doi:10.1053/j.gastro.2018.04.00829655836 22.PoordadF, SchiffER, VierlingJM, et al. Daclatasvir with" exact="sofosbuvir" post="and ribavirin for hepatitis C virus infection with advanced"/>
 <result pre="doi:10.1053/j.gastro.2018.04.00829655836 22.PoordadF, SchiffER, VierlingJM, et al. Daclatasvir with sofosbuvir and" exact="ribavirin" post="for hepatitis C virus infection with advanced cirrhosis or"/>
</results>
